The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution

References

• Organization WH, Cancer IAfRo. WHO Classification of Tumours of Soft Tissue and Bone. 2013.
   Google Scholar
• GaneshanD, AminiB, NikolaidisP, AssingM, VikramR. Current update on desmoid fibromatosis. J Comput Assist Tomogr. 2019;43(1):29–38. doi:10.1097/RCT.000000000000079030211798
   PubMed Web of Science ®Google Scholar
• BonvalotS, TernesN, FioreM, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096–4102. doi:10.1245/s10434-013-3197-x24052312
   PubMed Web of Science ®Google Scholar
• GronchiA, CasaliPG, MarianiL, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21(7):1390–1397. doi:10.1200/JCO.2003.05.15012663732
   PubMed Web of Science ®Google Scholar
• BriandS, BarbierO, BiauD, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am. 2014;96(8):631–638. doi:10.2106/JBJS.M.0098824740659
   PubMed Web of Science ®Google Scholar
• WangYF, GuoW, SunKK, et al. Postoperative recurrence of desmoid tumors: clinical and pathological perspectives. World J Surg Oncol. 2015;13(1):26. doi:10.1186/s12957-015-0450-825888954
   PubMed Web of Science ®Google Scholar
• GluckI, GriffithKA, BiermannJS, FengFY, LucasDR, Ben-JosefE. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80(3):787–792. doi:10.1016/j.ijrobp.2010.02.05320615622
   PubMed Web of Science ®Google Scholar
• KasperB, BaumgartenC, GarciaJ, et al. An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC)/soft tissue and bone sarcoma group (STBSG). Ann Oncol. 2017;28(10):2399–2408. doi:10.1093/annonc/mdx32328961825
   PubMed Web of Science ®Google Scholar
• YaoX, CorbettT, GuptaAA, et al. A systematic review of active treatment options in patients with desmoid tumours. Curr Oncol. 2014;21(4):e613–629. doi:10.3747/co.21.199525089111
   PubMed Web of Science ®Google Scholar
• GronchiA, ColomboC, Le PéchouxC, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm – a position paper from the Italian and the French sarcoma group. Ann Oncol. 2014;25(3):578–583. doi:10.1093/annonc/mdt48524325833
   PubMed Web of Science ®Google Scholar
• KeusRB, NoutRA, BlayJY, et al. Results of a Phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis – an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–2676. doi:10.1093/annonc/mdt25423868907
   PubMed Web of Science ®Google Scholar
• FioreM, ColomboC, RadaelliS, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer. 2015;51(18):2800–2807. doi:10.1016/j.ejca.2015.08.02626602014
   PubMed Web of Science ®Google Scholar
• WangZ, WuJ, TianX, HaoC. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects. Front Med. 2019;13(4):427–437. doi:10.1007/s11684-018-0672-630798508
   PubMed Web of Science ®Google Scholar
• ElnekaveE, AtarE, AmarS, et al. Doxorubicin-eluting intra-arterial therapy for pediatric extra-abdominal desmoid fibromatoses: a promising approach for a perplexing disease. J Vasc Interv Radiol. 2018;29(10):1376–1382. doi:10.1016/j.jvir.2018.04.00930075974
   PubMed Web of Science ®Google Scholar
• PalassiniE, FrezzaAM, MarianiL, et al. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J. 2017;23(2):86–91. doi:10.1097/PPO.000000000000025428410293
   PubMed Web of Science ®Google Scholar
• PenelN, CoindreJM, BonvalotS, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90–96. doi:10.1016/j.ejca.2016.02.00826974708
   PubMed Web of Science ®Google Scholar
• KasperB, BaumgartenC, BonvalotS, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise - a sarcoma patients EuroNet and European organisation for research and treatment of cancer/soft tissue and bone sarcoma group initiative. Eur J Cancer. 2015;51(2):127–136.25434922
   PubMed Web of Science ®Google Scholar
• ChughR, WathenJK, PatelSR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter sarcoma alliance for research through collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884–4891. doi:10.1158/1078-0432.CCR-10-117720724445
   PubMed Web of Science ®Google Scholar
• SzucsZ, MessiouC, WongHH, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421–426. doi:10.1097/CAD.000000000000047428099210
   PubMed Web of Science ®Google Scholar
• GounderMM, LefkowitzRA, KeohanML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011;17(12):4082–4090. doi:10.1158/1078-0432.CCR-10-332221447727
   PubMed Web of Science ®Google Scholar
• GounderMM, MahoneyMR, Van TineBA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417–2428. doi:10.1056/NEJMoa180505230575484
   PubMed Web of Science ®Google Scholar
• SunY, NiuW, DuF, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. doi:10.1186/s13045-016-0332-827716285
   PubMed Web of Science ®Google Scholar
• ChiY, FangZ, HongX, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-376629895706
   PubMed Web of Science ®Google Scholar
• TangL, YuW, WangY, LiH, ShenZ. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol. 2019;21(12):1624–1633. doi:10.1007/s12094-019-02090-230963468
   PubMed Web of Science ®Google Scholar
• HanB, LiK, ZhaoY, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–661. doi:10.1038/bjc.2017.47829438373
   PubMed Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• StacchiottiS, ColliniP, MessinaA, et al. High-grade soft-tissue sarcomas: tumor response assessment – pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009;251(2):447–456. doi:10.1148/radiol.251208140319261927
   PubMed Web of Science ®Google Scholar
• HeinrichMC, McArthurGA, DemetriGD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24(7):1195–1203. doi:10.1200/JCO.2005.04.071716505440
   PubMed Web of Science ®Google Scholar
• PenelN, Le CesneA, BuiBN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French sarcoma group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–457. doi:10.1093/annonc/mdq34120622000
   PubMed Web of Science ®Google Scholar
• KasperB, GruenwaldV, ReichardtP, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German interdisciplinary sarcoma group (GISG). Eur J Cancer. 2017;76:60–67. doi:10.1016/j.ejca.2017.02.00128282612
   PubMed Web of Science ®Google Scholar
• WilhelmSM, CarterC, TangL, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–7109. doi:10.1158/0008-5472.CAN-04-144315466206
   PubMed Web of Science ®Google Scholar
• ShenG, ZhengF, RenD, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120.30231931
   PubMed Web of Science ®Google Scholar
• WangHY, ChuJF, ZhangP, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma. Onco Targets Ther. 2020;13:1561–1568. doi:10.2147/OTT.S23534932110053
   PubMed Web of Science ®Google Scholar
• LuoJ, JinK, QianS, et al. Single institution experience of split course radiotherapy in patients with desmoid tumors. Onco Targets Ther. 2019;12:1741–1748. doi:10.2147/OTT.S18944930881028
   PubMed Web of Science ®Google Scholar
• WalkerEA, FentonME, SaleskyJS, MurpheyMD. Magnetic resonance imaging of benign soft tissue neoplasms in adults. Radiol Clin North Am. 2011;49(6):1197–1217. doi:10.1016/j.rcl.2011.07.00722024295
   PubMed Web of Science ®Google Scholar
• Gondim TeixeiraPA, BiouichiH, Abou ArabW, et al. Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. Eur Radiol. 2020;30(2):895–902. doi:10.1007/s00330-019-06404-431468156
   PubMed Web of Science ®Google Scholar
• ShethPJ, Del MoralS, WilkyBA, et al. Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol. 2016;45(10):1365–1373. doi:10.1007/s00256-016-2439-y27502790
   PubMed Web of Science ®Google Scholar